Discontinued — last reported Q4 '17
Non-Current Assets
Indefinite-Lived Research and Development Assets
PPG Industries Indefinite-Lived Research and Development Assets increased by 17.4% to $304.00M in Q4 2025 compared to the prior quarter. Year-over-year, this metric grew by 17.4%, from $259.00M to $304.00M. This is a positive signal — higher values indicate stronger performance for this metric.
Analysis
StatementBalance Sheet Statement
SectionNon-Current Assets
CategoryGrowth
SignalHigher is better
VolatilityModerate
First reportedQ3 2015
Last reportedQ4 2017
How to read this metric
An increase indicates aggressive investment in external innovation, while a decrease may signal project completion, commercialization, or impairment charges.
Detailed definition
This represents the value of acquired in-process research and development (IPR&D) projects that have not yet reached com...
Peer comparison
Common in pharmaceutical and medical device sectors where M&A is a primary driver of R&D pipelines.
Metric ID:
indefinite_lived_rd_assetsHistorical Data
5 periods
| Q4 '21 | Q4 '22 | Q4 '23 | Q4 '24 | Q4 '25 | |
|---|---|---|---|---|---|
| Value | $68.00M | $149.00M | $213.00M | $259.00M | $304.00M |
| QoQ Change | — | +119.1% | +43.0% | +21.6% | +17.4% |
| YoY Change | — | +119.1% | +43.0% | +21.6% | +17.4% |
Range$68.00M – $304.00M
CAGR+347.1%
Avg YoY Growth+50.3%
Median YoY Growth+32.3%
Current Streak4+ quarters growth
Indefinite-Lived Research and Development Assets at Other Companies
Frequently Asked Questions
- What is PPG Industries's indefinite-lived research and development assets?
- PPG Industries (PPG) reported indefinite-lived research and development assets of $304.00M in Q4 2025.
- How has PPG Industries's indefinite-lived research and development assets changed year-over-year?
- PPG Industries's indefinite-lived research and development assets increased by 17.4% year-over-year, from $259.00M to $304.00M.
- What does indefinite-lived research and development assets mean?
- The value of ongoing research projects acquired from other companies that are not yet ready for sale.